Lupin Limited (NSE: LUPIN; BSE: 500257) has secured a European commercialization position around one of the newest pharmacological approaches to presbyopia, with wholly owned subsidiary VISUfarma signing an exclusive licensing agreement for Tenpoint Therapeutics’ YUVEZZI across the European Union, United Kingdom, Switzerland, Norway and Iceland. VISUfarma will assume responsibility for regulatory activities, promotion, distribution and sales in those territories, while making a strategic investment in Visus Therapeutics, Tenpoint’s US subsidiary. Tenpoint and Visus can additionally receive undisclosed regulatory and commercial milestone payments and tiered royalties on net sales, meaning the economic value of the partnership will depend partly on regulatory progress and commercial uptake rather than a disclosed fixed acquisition price.
YUVEZZI is already approved in the United States as a once-daily combination of carbachol 2.75% and brimonidine tartrate 0.1% for adults with presbyopia, the age-related loss of near focusing ability that makes reading small text progressively more difficult. FDA approved the product in January 2026 after two controlled Phase 3 studies, and Tenpoint is now building regional commercialization partnerships rather than attempting to construct a direct sales organization in every geography. The UK Marketing Authorization Application has already been submitted through the Medicines and Healthcare products Regulatory Agency’s International Recognition Procedure, giving Lupin and Tenpoint an initial regulatory route into part of the licensed territory while additional European filings are prepared.
How does YUVEZZI improve near vision without replacing the eye’s aging lens?
Presbyopia develops largely because the eye’s natural lens becomes progressively less flexible with age, reducing its ability to change shape sufficiently for near focusing. Pupil-constricting eye drops do not reverse that structural aging. Instead, they create a pinhole-like optical effect by making the pupil smaller, increasing depth of focus so near objects can appear sharper even though the lens itself has not regained youthful accommodation.
YUVEZZI combines two pharmacological mechanisms intended to control that pupil response. FDA labeling describes carbachol as a cholinergic agonist that constricts the iris sphincter and ciliary body, while brimonidine inhibits the iris dilator muscle and relaxes tonic ciliary-muscle contraction. The combination is intended to produce a controlled reduction in pupil diameter while supporting carbachol availability within the eye, creating greater near-vision depth without relying on a surgical lens procedure.
This makes the drug part of a growing category competing against reading glasses, multifocal contact lenses and surgical correction rather than replacing those options universally. Pharmacological presbyopia treatment is temporary and requires repeat dosing, but it offers something glasses do not: near-vision improvement without carrying or putting on another optical device.
What did the BRIO studies show about how quickly the eye drop works?
FDA’s prescribing information bases YUVEZZI efficacy on two randomized, double-masked Phase 3 trials involving adults aged 45 to 80. BRIO I used a crossover design in 182 participants comparing YUVEZZI with each active component individually, while BRIO II randomized 436 participants to YUVEZZI or vehicle and included six months of once-daily use followed by a six-month open-label extension. The principal visual endpoint examined the percentage of participants gaining at least three lines, equivalent to 15 letters, in binocular uncorrected near visual acuity without losing at least one line in binocular uncorrected distance vision.
The effect appeared quickly. In BRIO II, 19.4% of YUVEZZI-treated participants met the three-line near-vision endpoint 30 minutes after dosing compared with 1.8% receiving vehicle, while at one hour the respective proportions were 38.2% and 3.7%. At two hours, 34.1% of YUVEZZI recipients achieved the endpoint versus 3.7% with vehicle, and the difference remained statistically significant at eight hours, when 10.2% of YUVEZZI participants met the endpoint compared with 3.2% receiving vehicle.
BRIO I adds an important component-level comparison. YUVEZZI generally outperformed carbachol or brimonidine alone during the period of strongest effect, suggesting that combining the two mechanisms contributes more than simply placing an already effective single agent into a new brand. The absolute responder rates also show that the medicine is not equivalent to restoring natural accommodation in every patient, which will matter when clinicians set expectations.
What safety considerations come with shrinking the pupil pharmacologically?
A smaller pupil improves depth of focus but allows less light into the eye, creating an inherent trade-off between near vision and performance under dim conditions. FDA therefore warns patients that temporary dim or dark vision can occur and advises caution during night driving or other hazardous activity in poor illumination. Temporary blurred vision or difficulty changing focus between near and distant objects can also occur, and patients should not drive or operate machinery when vision is unclear.
More serious ocular warnings include retinal tear or detachment, particularly in individuals with pre-existing retinal disease, as well as caution in patients with iritis. FDA advises retinal examination before initiating therapy and directs patients to seek urgent medical evaluation for sudden flashes, floaters or vision loss. The label also includes vascular precautions associated with brimonidine and potential interactions with antihypertensive medicines, cardiac glycosides, central nervous system depressants and monoamine oxidase inhibitors.
The most frequently reported adverse reactions exceeding 5% included eye pain during instillation, visual impairment, eye irritation after dosing and headache. These considerations are commercially important because presbyopia is not a life-threatening disease, meaning patients may have relatively low tolerance for adverse effects when reading glasses provide a simple alternative.
Why does YUVEZZI fit Lupin’s VISUfarma strategy?
VISUfarma gives Lupin an established specialist ophthalmology organization rather than forcing the Indian pharmaceutical group to build a European eye-care commercialization platform around one product. Presbyopia treatment is particularly dependent on optometrists and ophthalmologists explaining which patients are suitable, setting expectations around duration and managing visual side effects, so specialty commercial access may matter more than broad primary-care promotion.
The licensing structure also lets Tenpoint concentrate resources on the United States and other selected regions while monetizing markets where a partner already possesses infrastructure. Lupin receives a differentiated branded product for its European eye-care portfolio, while Tenpoint preserves downstream participation through milestones and royalties rather than selling the regional asset outright.
The strategic investment adds another layer because Lupin is not merely paying for distribution rights. Although the amount was not disclosed, an equity-style investment in Visus gives the relationship a financial component tied to the broader development of the product and company. Investors should therefore resist treating the absence of a headline transaction value as evidence that the partnership is economically insignificant.
How difficult will the European presbyopia market be to build?
The addressable population is enormous because nearly everyone eventually develops some degree of presbyopia, but prevalence does not automatically become a prescription-drug market. Reading glasses are inexpensive, familiar and effective, while patients can also choose contact lenses or refractive procedures. A daily prescription eye drop therefore has to create enough convenience and visual benefit to justify cost, repeat use and potential side effects.
YUVEZZI’s differentiation is its dual-agent once-daily formulation and clinical evidence supporting improvement within 30 minutes and lasting effects across several hours. Yet response varies substantially across patients, and the proportion reaching the strict three-line endpoint falls as the day progresses. The commercial opportunity may consequently center on patients who value periods of spectacle independence rather than those expecting one drop to restore youthful near vision continuously.
Lupin and Tenpoint now have to translate US regulatory validation into European demand. The deal gives YUVEZZI a partner with established regional ophthalmology infrastructure and provides Lupin with a differentiated prescription asset, but the more consequential question is whether pharmacological presbyopia becomes a durable treatment category rather than a niche convenience product in a market where the principal competitor still costs only a few dollars and requires no prescription.
